Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Semaglutide Formulations (DV3396 vs PDS290) in Overweight or Obesity
NCT04187300Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2019
- Primary completion
- Sep 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of semaglutide in obesity and Overweight (2 arms), sponsored by Novo Nordisk. Primary endpoints: Area under the semaglutide concentration time curve (0-168 hours) at steady state (2.4 mg) and Maximum observed semaglutide concentration at steady state (2.4 mg). Started Dec 2019; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT04187300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04187300.